

Novel Oral Anticoagulants Prior Authorization of Benefits Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004. Provider Help Desk: 1-800-454-3730

1. Patient information		2. Physician information		
Patient name:		Prescribing physician:		
Patient ID #:		Physician address:		
Patient DOB:		Physician phone #:		
Date of Rx:		Physician fax #:		
Patient phone #:		Physician specialty:		
Patient email address:		Physician DEA:		
		Physician NPI #:		
		Physician email address:		
3. Medication	4. Strength	5. Directions	6. Quantity per 30 days	
			Specify:	
7. Diagnosis:				
8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your				
patient and may affect the outcome of this request.)				
Prior authorization (PA) is not required for preferred novel oral anticoagulants (NOACs). PA is required for				
nonpreferred NOACs. Requests for doses outside of the manufacturer recommended dose will not be considered.				
Payment will be considered for FDA approved or compendia indications under the following conditions:				
1. Patient does not have a mechanical heart valve.				
2. Patient does not have active bleeding.				
3. For a diagnosis of atrial fibrillation or stroke prevention, patient has the presence of at least 1 additional risk				
factor for stroke, with a CHA_2DS_2 -VASc score ≥ 1 .				
4. A recent creatinine clearance (CrCl) is provided.				
5. A recent Child-Pugh	score is provided.			

- 6. Patient's current body weight is provided.
- 7. Patient has documentation of a trial and therapy failure at a therapeutic dose with at least two preferred NOACs.
- 8. For requests for edoxaban, documentation patient has had 5 to 10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated heparin). The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Nonpreferred

□ Savaysa

Preferred (no PA required if within established quantity limits)

- □ Eliquis □ Xarelto
- Pradaxa

Diagnosis:					
Does patient have mechanical heart valve? Yes No					
Does patient have active bleeding? Yes No					
Patient body weight: Date obtained:					
Provide recent creatinine clearance (CrCl): Date obtained:					
Provide recent Child-Pugh score: Date completed:					
Requests for a diagnosis of atrial fibrillation or stroke prevention:					
Risk factor based CHA ₂ DS ₂ -VASc score					
Risk factors	Score				
□ Congestive heart failure	1				
□ Hypertension	1				
□ Age ≥ 75 years	2				
☐ Age between 65 and 74 years	1				
□ Stroke / TIA / TE	2				
□ Vascular disease (previous MI, peripheral arterial disease or aortic plaque)	1				
Diabetes mellitus	1				
Female	1				
Total					
Document 2 preferred NOAC trials Preferred NOAC Trial 1: Name/dose:					
Proferred NOAC Trial 2:					
Preferred NOAC Trial 2: Name/dose: Trial dates:					
Failure reason:					
Requests for edoxaban (Savaysa) Provide documentation of 5-10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated heparin): Drug name and dose: Trial dates:					
Medical or contraindication reason to override trial requirements:					
Attach lab results and other documentation as necessary.					

9. Physician signature

Prescriber or authorized signature

Date

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.